ASCO 2026: Selpercatinib shows decrease in risk of disease recurrence or death as adjuvant therapy for early-stage RET fusion-positive NSCLC
Adjuvant treatment with the targeted therapy drug selpercatinib can help reduce the risk that cancer…
Browsing: Featured Events
ASCO 2026: Digital symptom monitoring with nurse support helps maintain quality of life in advanced cancer
A digital symptom monitoring program supported by palliative care nurses helped maintain quality of life…
AACR 2026: New antibody-drug conjugate shows clinical benefit for advanced platinum-resistant ovarian cancer
Patients with advanced platinum-resistant ovarian cancer whose disease had progressed on standard therapy experienced clinical…
AACR 2026: Novel approach prevents cancer progression, spares surgery for majority of patients with precancerous oral lesions
Direct injection of a low dose of the immune checkpoint inhibitor nivolumab into precancerous oral…
EBCC15: Breast cancer recurrence remains low, even after ten years, with radiotherapy tailored to patient’s individual risk
The chances of breast cancer recurring remain very low when patients are treated with radiotherapy…
EAU 2026: Scan that makes prostate cancer cells glow could cut need for biopsies
Findings from the PRIMARY2 trial are presented at the European Association of Urology Congress in…
ASCO GU 2026: Hormone therapy may not benefit most men receiving radiotherapy after prostate surgery
A new study led by UCLA Health Jonsson Comprehensive Cancer Centre investigators suggests that adding hormone therapy…
ASCO GI 2026: Zanidatamab and chemotherapy can slow cancer growth, extend survival in some people with gastroesophageal adenocarcinoma
Results from a new phase 3 study found that for people with human epidermal growth…
SABCS 2025: Study solves a long-standing gap in metastatic breast cancer research and care: accurately measuring treatment response in patients with bone metastases
A prospective, multicenter cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) has validated…
ASH 2025: ‘Ready-made’ T-cell gene therapy tackles ‘incurable’ T-cell leukaemia
A groundbreaking new treatment using genome-edited immune cells, developed by scientists at UCL (University College…